RBM10 and lung adenocarcinoma: In RBM10-deficient lung adenocarcinoma, combining a spliceosome inhibitor with the EGFR tyrosine kinase inhibitor (Osimertinib) improves therapeutic efficacy and reduces drug resistance, offering a promising treatment strategy 16, 17.